The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Long-term follow-up of pirtobrutinib therapy in Waldenström’s macroglobulinemia: the BRUIN trial
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses long-term follow-up of pirtobrutinib therapy in Waldenström’s macroglobulinemia from the Phase Ib/II BRUIN trial (NCT03740529). Dr Cheah highlights encouraging long-term progression-free survival rates and duration of response, regardless of prior exposure to BTK inhibitors. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
BRUIN was a very large phase 1b/2 trial evaluating the non-covalent BTK inhibitor pirtobrutinib in a range of different B-cell malignancies. At this meeting, I’m updating the results for the 80 patients with Waldenström macroglobulinemia that were treated with pirtobrutinib. This was a mixture of patients treated on both phase 1b and phase 2, although the majority of patients received the recommended phase 2 dose of 200 milligrams...
BRUIN was a very large phase 1b/2 trial evaluating the non-covalent BTK inhibitor pirtobrutinib in a range of different B-cell malignancies. At this meeting, I’m updating the results for the 80 patients with Waldenström macroglobulinemia that were treated with pirtobrutinib. This was a mixture of patients treated on both phase 1b and phase 2, although the majority of patients received the recommended phase 2 dose of 200 milligrams. 63 patients were BTK exposed and 17 patients were BTK naive. But really, although we’ve presented the overall results previously in terms of the response rates, we present updated follow-up median of 33 months and pretty encouraging long-term PFS rates and duration of response in patients treated with pirtobrutinib irrespective of exposure to prior BTK inhibitors. This is important because patients with disease progression after covalent BTK inhibitors actually have very few approved therapies and the activity and safety of pirtobrutinib in this setting is very encouraging.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
